Integrins as attractive targets for cancer therapeutics
Integrins are transmembrane receptors that have been implicated in the biology of various human physiological and pathological processes. These molecules facilitate cell–extracellular matrix and cell–cell interactions, and they have been implicated in fibrosis, inflammation, thrombosis, and tumor me...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-09-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383521000071 |
| _version_ | 1830188245757984768 |
|---|---|
| author | Meng Li Ying Wang Mengwei Li Xuezhen Wu Sarra Setrerrahmane Hanmei Xu |
| author_facet | Meng Li Ying Wang Mengwei Li Xuezhen Wu Sarra Setrerrahmane Hanmei Xu |
| author_sort | Meng Li |
| collection | DOAJ |
| description | Integrins are transmembrane receptors that have been implicated in the biology of various human physiological and pathological processes. These molecules facilitate cell–extracellular matrix and cell–cell interactions, and they have been implicated in fibrosis, inflammation, thrombosis, and tumor metastasis. The role of integrins in tumor progression makes them promising targets for cancer treatment, and certain integrin antagonists, such as antibodies and synthetic peptides, have been effectively utilized in the clinic for cancer therapy. Here, we discuss the evidence and knowledge on the contribution of integrins to cancer biology. Furthermore, we summarize the clinical attempts targeting this family in anti-cancer therapy development. |
| first_indexed | 2024-12-17T22:41:44Z |
| format | Article |
| id | doaj.art-6849037c24a943ca8d887e303d3905b3 |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-12-17T22:41:44Z |
| publishDate | 2021-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-6849037c24a943ca8d887e303d3905b32022-12-21T21:29:54ZengElsevierActa Pharmaceutica Sinica B2211-38352021-09-0111927262737Integrins as attractive targets for cancer therapeuticsMeng Li0Ying Wang1Mengwei Li2Xuezhen Wu3Sarra Setrerrahmane4Hanmei Xu5Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, ChinaState Key Laboratory of Natural Medicines, Ministry of Education, the Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Department of Marine Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaState Key Laboratory of Natural Medicines, Ministry of Education, the Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Department of Marine Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaAffiliated Hospital of Chifeng College, Inner Mongolia Autonomous Region 024005, ChinaState Key Laboratory of Natural Medicines, Ministry of Education, the Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Department of Marine Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaState Key Laboratory of Natural Medicines, Ministry of Education, the Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Department of Marine Pharmacy, China Pharmaceutical University, Nanjing 211198, China; Corresponding author.Integrins are transmembrane receptors that have been implicated in the biology of various human physiological and pathological processes. These molecules facilitate cell–extracellular matrix and cell–cell interactions, and they have been implicated in fibrosis, inflammation, thrombosis, and tumor metastasis. The role of integrins in tumor progression makes them promising targets for cancer treatment, and certain integrin antagonists, such as antibodies and synthetic peptides, have been effectively utilized in the clinic for cancer therapy. Here, we discuss the evidence and knowledge on the contribution of integrins to cancer biology. Furthermore, we summarize the clinical attempts targeting this family in anti-cancer therapy development.http://www.sciencedirect.com/science/article/pii/S2211383521000071IntegrinsExtracellular matrixTumor progressionTargeted drugAntagonistsClinical trial |
| spellingShingle | Meng Li Ying Wang Mengwei Li Xuezhen Wu Sarra Setrerrahmane Hanmei Xu Integrins as attractive targets for cancer therapeutics Acta Pharmaceutica Sinica B Integrins Extracellular matrix Tumor progression Targeted drug Antagonists Clinical trial |
| title | Integrins as attractive targets for cancer therapeutics |
| title_full | Integrins as attractive targets for cancer therapeutics |
| title_fullStr | Integrins as attractive targets for cancer therapeutics |
| title_full_unstemmed | Integrins as attractive targets for cancer therapeutics |
| title_short | Integrins as attractive targets for cancer therapeutics |
| title_sort | integrins as attractive targets for cancer therapeutics |
| topic | Integrins Extracellular matrix Tumor progression Targeted drug Antagonists Clinical trial |
| url | http://www.sciencedirect.com/science/article/pii/S2211383521000071 |
| work_keys_str_mv | AT mengli integrinsasattractivetargetsforcancertherapeutics AT yingwang integrinsasattractivetargetsforcancertherapeutics AT mengweili integrinsasattractivetargetsforcancertherapeutics AT xuezhenwu integrinsasattractivetargetsforcancertherapeutics AT sarrasetrerrahmane integrinsasattractivetargetsforcancertherapeutics AT hanmeixu integrinsasattractivetargetsforcancertherapeutics |